Whole genome sequencing in high-grade cervical intraepithelial neoplasia patients from different ethnic groups in China.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
10 Nov 2023
10 Nov 2023
Historique:
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
ppublish
Résumé
Cervical cancer (CC) is the fourth most common cancer in women worldwide. It develops through precancerous lesions (cervical intraepithelial neoplasia (CIN), graded from low-grade (CIN1) to high-grade (CIN2-3)). It is well established that precancerous and cancerous cervical lesions are caused by a persistent infection with high-risk types of the human papilloma virus (hrHPV). To have a deeper understanding of the pathogenesis of CIN and CC, we systematically analyzed the landscape of genomic alterations and HPV integration profiles in high-grade CIN2/3. We performed deep whole genome sequencing on exfoliated cervical cells and matched peripheral blood samples from a cohort of 51 Chinese patients (of whom 35 were HPV+) with high-grade CIN from 3 ethnic groups and constructed strict integrated workflow of genomic analysis. In addition, the HPV types and integration breakpoints in the exfoliated cervical cells from these patients were examined. Genomic analysis identified 6 significantly mutated genes (SMGs), including CDKN2A, PIK3CB, FAM20A, RABEP1, TMPRSS2 and SS18L1, in 51 CIN2/3 samples. As none of them had previously been identified as SMGs in the Cancer Genome Atlas cervical squamous cell carcinoma and endocervical adenocarcinoma (TCGA-CESC) cohort, future studies with larger sample size of CINs may be needed to validate our findings. Mutational signature analysis showed that mutational signatures of CINs were dramatically different from CCs, highlighting their different mutational processes and etiologies. Moreover, non-silent somatic mutations were detected in all of the CIN2/3 samples, and 88% of these mutations occurred in genes that also mutated in CCs of TCGA cohort. CIN2 samples had significantly less non-silent mutations than CIN3 samples (P = .0006). Gene ontology and pathway level analysis revealed that functions of mutated genes were significantly associated with tumorigenesis, thus these genes may be involved in the development and progression of CC. HPV integration breakpoints occurred in 28.6% of the CIN2/3 samples with HPV infection. Integrations of common high risk HPV types in CCs, including HPV16, 52, 58 and 68, also occurred in the CIN samples. Our results lay the groundwork for a deeper understanding of the molecular mechanisms underlying the pathogenesis of CC and pave the way for new tools for screening, diagnosis and treatment of cervical precancerous and cancerous lesions.
Identifiants
pubmed: 37960754
doi: 10.1097/MD.0000000000035953
pii: 00005792-202311100-00041
pmc: PMC10637475
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e35953Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Nucleic Acids Res. 2022 Jul 5;50(W1):W216-W221
pubmed: 35325185
Lancet Oncol. 2008 May;9(5):425-34
pubmed: 18407790
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
J Med Genet. 2019 Mar;56(3):186-194
pubmed: 30567904
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2536-45
pubmed: 18842994
J Pathol. 2006 Jan;208(2):152-64
pubmed: 16362994
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
BMC Infect Dis. 2014 Jul 12;14:388
pubmed: 25016305
Am J Epidemiol. 2013 Oct 1;178(7):1161-9
pubmed: 23897645
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nat Rev Cancer. 2014 Jun;14(6):395-405
pubmed: 24854082
Lancet. 2004 Jul 17-23;364(9430):249-56
pubmed: 15262102
J Transl Med. 2014 Sep 16;12:255
pubmed: 25220666
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3033-42
pubmed: 18957520
Clin Transl Oncol. 2021 Feb;23(2):222-228
pubmed: 32594303
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Curr Probl Cancer. 2020 Oct;44(5):100567
pubmed: 32201051
Ann Oncol. 2011 Dec;22(12):2675-2686
pubmed: 21471563
Cell Genom. 2022 Nov 09;2(11):None
pubmed: 36388765
Front Oncol. 2021 Jun 17;11:672386
pubmed: 34221990
Nat Genet. 2015 Feb;47(2):158-63
pubmed: 25581428
Nature. 2014 Feb 20;506(7488):371-5
pubmed: 24390348
NAR Genom Bioinform. 2022 Apr 26;4(2):lqac032
pubmed: 35493723
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Lancet Oncol. 2014 Mar;15(3):315-22
pubmed: 24529697